A multi-center, open-lable, phase I trial of RG-101 in healthy volunteers and patients with hepatitis C virus infection with severe renal impairment
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 27 Jun 2016
At a glance
- Drugs RG 101 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- 27 Jun 2016 According to a Regulus Therapeutics media release, the company is on track to deliver follow-up results from this study at upcoming relevant scientific meetings.
- 27 Jun 2016 Status changed from recruiting to active, no longer recruiting, according to a Regulus Therapeutics media release.
- 27 Jun 2016 According to a Regulus Therapeutics media release, the company plans to work with US FDA to seek the release of the clinical hold.